स्वास्थ्य सम्बन्धी सम्पूर्ण जानकारी

جميع المعلومات المتعلقة بالصحة

Lahat ng impormasyong may kaugnayan sa kalusugan

स्वास्थ्य संबंधी सारी जानकारी

Semua maklumat berkaitan kesihatan

ကျန်းမာရေးဆိုင်ရာ အချက်အလက်အားလုံး

ຂໍ້ມູນທີ່ກ່ຽວຂ້ອງກັບສຸຂະພາບທັງໝົດ

Dhammaan macluumaadka la xiriira caafimaadka

स्वास्थ्यसम्बद्धाः सर्वाणि सूचनानि

Alle gezondheidsgerelateerde informative

Tota la informació relacionada amb la salut

ሁሉም ከጤና ጋር የተያያዙ መረጃዎች

ព័ត៌មានទាក់ទងនឹងសុខភាពទាំងអស់។

صحت سے متعلق تمام معلومات

Mọi thông tin liên quan đến sức khỏe

The Health Thread Logo

The Health Thread

From shadow to light: Supporting unhoused persons to access lifesaving TB services

The risk of getting TB disease is among the highest in unhoused and other marginalised persons but the likelihood of them seeking public TB services is low – and finishing lifesaving TB therapy is even lower. The delay is long – very long – for them to get right diagnosis (if at all) – and so are the catastrophic costs which they may incur until getting correctly diagnosed. Not being able to finish lifesaving TB treatment is not helping either- the person suffers and so does the TB response – because we collectively fail to disrupt TB transmission. 

At the world’s largest conference on TB and lung diseases, a couple of scientific presentations provide a strong beam of light to address TB with success (and in a person-centred manner) among those who are at one of the highest risks (of getting the disease – as well as of being left behind).

 Jahangeer Alam, a TB survivor and champion himself, made two important scientific presentations at World Conference on Lung Health in Copenhagen, Denmark. He works with Humana People to People India (HPPI).

Journeying from shadow to light

It is humbling to listen to real experiences of unhoused persons of their journeys from dark shadows in the lung towards treatment and care, and from services that were inaccessible earlier towards receiving person-centred care and getting cured of TB – thanks to HPPI and support and partnership of Indian government’s National TB Elimination Programme (NTEP) and its partners on the ground.

 Jahangeer shared with the delegates of the world conference some of the key learnings from HPPI’s experiences of working with unhoused persons in India since 2017.

Timeless wisdom of Margaret Mead’s words come to life when we hear Jahangeer speak: “Never doubt that a small group of thoughtful committed individuals can change the world. In fact, it’s the only thing that ever has.”

HPPI implemented 7 initiatives during 2017-2025 to find more TB among the unhoused persons in Delhi, India and link them to public services. HPPI developed a person-centred, rights-based, and gender transformative model to do so. There were estimates that the number of unhoused persons in Delhi could be around 300,000.

During 2017-2025, frontline healthcare workers of HPPI reached out to 225,022 unhoused persons who were highly vulnerable to TB and hard to reach. Out of those screened for TB, 10,976 people were found with presumptive TB and offered a (free) confirmatory TB test in government facility. 2283 unhoused persons were found to have active TB disease and 53 of them had a very serious form of TB, referred to as drug-resistant TB (where TB bacteria become resistant to some of the most powerful anti-TB medicines).

Overall, for every 99 unhoused persons screened for TB, 1 was found with active TB disease between 2017-2025 by HPPI. However, in some areas or projects, this rate was alarmingly high: 1 in every 44 screened for TB had the disease.

 Making a difference

 When HPPI began working with unhoused persons in 2017, a lot of them dropped out of care. 15% was the loss to follow up rate. And dropping out of lifesaving TB treatment meant that the person continues to suffer, has higher risk of TB death, and the disease keeps spreading to others (if the person had lung TB). Death rate among the unhoused peoples in 2017 who were on TB treatment was 8.8%.

 HPPI model demonstrated that it is possible to reduce human suffering and save lives: loss to follow up rate dropped to 1.7% by 2024 (from 15% in 2017), and TB death rate dropped to 2.5% by 2024 (from 8.8% in 2017).

 Jahangeer explained that there were 3 groups of unhoused persons HPPI was working with: those living on the roadside, shelters and temporary slums (referred to as ‘jhuggi’).

 “Unhoused persons had higher TB vulnerability because of several reasons: higher substance use (such as alcohol, tobacco or drugs), living in unhygienic conditions, low TB awareness and health literacy, and a range of access barriers to reach public health services. Lack of government identity documents, gender identities, fear of discrimination or losing daily wage were other barriers we found that blocked access to existing services,” said Jahangeer.

 In-person follow up and support to unhoused persons based on HPPI model was a gamechanger

 Jahangeer Alam shared that trained frontline healthcare workers to implement the HPPI model were critical to follow up and support unhoused persons. Those with TB disease and receiving treatment could finish the therapy successfully, thanks to the workers on the ground.

 HPPI had established a flexible partnership with local private X-Ray laboratories so that unhoused persons could be brought by their workers to get X-Ray screening at a community-convenient time (for example, early morning or late evening if convenient to the person being screened). “Typical 9am to 5pm would not work for most of them. Community-convenient and friendly timing must be adopted,” said Jahangeer.

 HPPI workers helped collect and take quality sputum samples of unhoused persons to government laboratories for confirmatory testing. For those with active TB disease, workers accompanied them for initiation of treatment from the nearest government centre.

 Daily follow up during the first 2 weeks after initiation of TB treatment, and then at least once weekly follow up till the person got cured, proved very helpful to ensure the unhoused person could adhere to TB therapy. Counselling, facilitating medical consultations in government centres as needed for side effect management or other healthcare needs, facilitating access of unhoused persons to social welfare schemes such as nutrition, financial support directly transferred by the government of India to their bank account during TB treatment every month, and other such benefits could also happen because of the assistance provided by HPPI workers on the frontline.

 Linkage to local community people also proved important because location of unhoused persons kept changing on an ongoing basis. HPPI workers identified such local allies and fostered these relationships. These allies included unhoused persons who were cured of TB (TB survivors who became TB champions), local vendors, caretakers of night shelter homes, among others. These allies were very helpful for HPPI workers to follow up with unhoused persons on an ongoing basis.

 “Intensified treatment adherence support is lifeline. We need to make this available to every unhoused person if we want them to adhere to the treatment and finish it. Field officer is needed on the ground if we want favourable TB programme outcomes from high-risk TB populations,” stressed Jahangeer.

 HPPI screened unhoused persons for TB using a range of approaches: verbal screening, X-Ray screening and AI-based cough screening (cough screening is being tested currently, showing promising initial results, but is not yet a part of government programme).

 Those who were found presumptive for TB were offered a confirmatory TB test at the nearest government-run facility (thanks to NTEP).

 But even sputum collection could become a challenge. Multiple efforts were needed in some instances and support of local communities remained vital, said Jahangeer – reemphasising the need of trained frontline workers to support unhoused persons regularly.

 Reducing diagnostic delays is key

 Leveraging, Engaging and Advocating to Disrupt TB transmission (LEAD) is another flagship initiative of HPPI that has demonstrated robust impact in reaching to unhoused and other marginalised persons in urban areas of India. “According to several studies in India, delay in TB diagnosis contributes to increased TB transmission, morbidity and higher mortality especially among marginalised populations, such as those living on the roadside, under flyovers, or in very temporary structures,” said Jahangeer Alam at the World Conference on Lung Health 2025. “Reducing diagnostic delays also reduces out of pocket expenses.” Delay in diagnosis also fails us in breaking the chain on infection transmission. We cannot end TB unless we disrupt TB transmission and take care of everyone with the TB bacteria in a science-based and person-centred manner.

 There is also a deadly synergy between diagnostic delays and catastrophic costs – both need to be eliminated if we are to ensure all those in need can access public services in a person-centred manner.

 “In 2024-2025, the turnaround time from identifying a person with presumptive TB to correct diagnosis for 75% of people was less than 5 days, and for 92% of them it was less than 10 days,” said Jahangeer. “Remaining 8% people took longer time as they needed further medical tests.”

 Three-fold increase in molecular testing

 During May 2023 and April 2024, LEAD-1 was first implemented during which 30% of those with presumptive TB were offered WHO-recommended upfront molecular testing in nearest government-run health facility (thanks to NTEP). Rest of them were offered microscopy (or were bacteriologically not confirmed and put on treatment upon expert medical advice).

 But in LEAD-2 (October 2024-January 2025, which was disrupted due to funding cuts and reinitiated recently), upfront molecular testing increased by almost 3 times to around 90%.

 This is a major science- and evidence-based difference HPPI could demonstrate with support from NTEP. Sputum microscopy underperforms in diagnosing TB (misses 50-60% of TB cases). That is why WHO called upon countries in 2018 to completely replace microscopy by 2027 with upfront molecular testing (that finds almost all TB and also tests if TB bacteria is resistant or sensitive to rifampicin – one of the most powerful anti-TB drugs). Political Declaration adopted at 2023 United Nations General Assembly High Level Meeting on TB re-echoes this promise to offer upfront molecular testing to 100% of those with presumptive TB. We cannot miss TB if we are to end TB. Right and timely diagnosis is entry gate to right treatment, care and support.

 Jahangeer underlines HPPI’s approach of encouraging unhoused persons to seek healthcare, be aware of their rights, and seek public services including social welfare support. Street plays to engaging people especially cured ones in public awareness rallies and other such initiatives have proven helpful.

 If we are to end TB and deliver on SDG-3 goal of ensuring all are healthy where no one is left behind, we need to scale up proven initiatives like that of HPPI and serve those who are most underserved.


Shobha Shukla, Bobby Ramakant – CNS

(Shobha Shukla is the founding Managing Editor of CNS (Citizen News Service) and Bobby Ramakant works as CNS Health Editor. Both are on the boards of Global Antimicrobial Resistance Media Alliance (GAMA) and Asia Pacific Media Alliance for Health, Gender and Development Justice (APCAT Media). Follow them on Twitter/X: @Shobha1Shukla, @BobbyRamakant, @CNS_Health

Tobacco-free and nicotine-free future is a bedrock to deliver on #EndTB and SDGs

According to the latest WHO Global TB Report 2025 released a week ago, tobacco smoking is among the top-5 risk factors for the deadliest of all infectious diseases worldwide – tuberculosis (TB). In countries with alarmingly high tobacco use, like Indonesia, tobacco use is the biggest risk factor for TB. Tobacco is also among the major common risk factors for a range of other non-infectious (or non-communicable) diseases, such as heart diseases and stroke, cancers, diabetes, chronic respiratory diseases, among others.

 If we are to protect people from TB or other deadly diseases and avert untimely deaths, the writing on the wall is clear: end all forms of tobacco and nicotine use. If we can protect human beings and our planet from tobacco and nicotine, we will majorly help governments implement lifesaving health policies and address infectious and non-communicable diseases effectively. Holding tobacco and nicotine industry liable for the deadly harm they are causing to human life and our planet remains critical too.

 No one should suffer or die of tobacco or nicotine use

 “Tobacco use is the single largest preventable cause of death globally. Over 8 million people die of tobacco use every year in the world. We can entirely prevent this manmade (or tobacco industry propelled) epidemic,” said Dr Tara Singh Bam, a noted global health leader and tobacco control advocate. Dr Bam serves as Asia Pacific Director (Tobacco Control) of Vital Strategies and Board Director of Asia Pacific Cities Alliance for Health and Development (APCAT), and till recently led International Union Against Tuberculosis and Lung Disease (The Union) in the Asia Pacific region. 

Dr Bam is right: Good news is that all 3: TB, nicotine and tobacco are preventable. We need to support all tobacco and nicotine users and help them quit, become tobacco-free and nicotine-free – and protect others from such deadly products. Also, we have to ensure that we are protecting everyone from TB and ensuring that right and timely diagnosis, correct treatment, care and support is accessible to everyone with TB disease in a person-centred manner, said Dr Bam.

TNT is explosive: Tobacco, Nicotine and TB

Tobacco smoking increases the risk of developing TB and makes TB treatment less effective – and – heightens risk of many other deadly diseases too.

Extensive scientific research underlines tobacco smoking’s substantial role in TB, amplifying the risk of infection, death, treatment relapse, heightened clinical severity, and delays in both: diagnosis and treatment, said Dr Bam. He was chairing an important hybrid session at the world’s largest lung health conference, formally known as Union World Conference on Lung Health in Copenhagen, Denmark.

Delayed diagnosis and treatment also means that the person with TB suffers more, has a higher risk of TB death, while the infection spreads to potentially more people – all of this is so avoidable.

 Tobacco use worsens TB outcomes, said Dr Bam while calling upon integrating smoke free policies and tobacco and nicotine cessation efforts into TB programmes.

 Agrees Dr Rakesh Gupta, Chairperson of Tobacco Control section of The Union: There is enough robust scientific evidence to effectively integrate tobacco cessation in TB programmes because it will yield very favourable public health outcomes, economic outcomes and social welfare outcomes. Evidence is there. Time is to really transform the science and evidence into policy, and policy into practice.

 Nicotine has been proven to be as addictive as cocaine and heroin and could even be more addictive. There is no doubt that if we are to live our lives healthy, we need to stay tobacco-free and nicotine-free.

 Dr Rakesh Gupta recommended evidence-based strategy that on every visit, a patient should be asked about tobacco use history along with brief advice on quitting and cessation support as needed. He also recommended that we should record this data (of tobacco use history) in TB treatment cards and registers.

We can prevent 15% TB cases if we help people quit tobacco use

“We can prevent 15% of the new TB cases if we stop tobacco smoking,” said Dr Akihiro Ohkado, Head of the Department of Epidemiology and Clinical Research, Research Institute of TB, Japan Anti-TB Association, Japan. He reemphasised that tobacco smoking significantly contributes to TB diagnostic delays, decreases TB treatment success rates, and also increases the risk of TB release.

Tobacco use steals away the gains made in TB control. Likewise, tobacco and nicotine use are also threatening the gains made in addressing major killers like heart diseases and stroke, cancers, diabetes, chronic respiratory diseases, among others.

Passive tobacco smoking is dangerous too

1 in 10 of tobacco-related deaths are due to passing tobacco smoking every year. Breathing must be smoke-free as a matter of human right.

Dr Tara Singh Bam also reminded the delegates of world conference that despite tobacco being a major risk factor for several lung diseases (like TB, asthma, COPD, among others), it is not a major focus area of world conference on lung health in Copenhagen.

Since TB patients are closely monitored by national TB programmes for the duration of the treatment – 6 months or more – it is an important opportunity to ensure they remain free of tobacco or nicotine use, alcohol use, and do active health promotion.

 We cannot dislocate #endTB goal from SDGs

There are a lot of doable science and evidence-based actions that must get implemented locally. Some of these are – raising awareness about “saying no to all forms of tobacco and nicotine use”, screening people for both (tobacco use and TB), early and accurate TB detection and linkage to care, linking those with tobacco use to cessation services, treatment adherence support, ending all forms of TB related stigma, engaging TB survivors meaningfully to make a difference, implementing the full package of evidence-based tobacco control interventions recommended by the WHO (including raising taxes and smoke-free policies), ensuring that effective tobacco cessation services are functional across the healthcare facilities, and, most importantly, protecting public health from tobacco industry interference.

Tobacco industry interference in public health policy is the biggest obstacle in implementing tobacco control policies. That is why the legally binding global tobacco treaty, formally called the WHO Framework Convention on Tobacco Control, has an important Article 5.3 that was adopted by governments in 2008. Preamble of WHO FCTC Article 5.3 clearly states to protect public health policy from tobacco industry interference because there is a direct and irreconcilable conflict of interest between the two. WHO FCTC Article 19 calls to hold tobacco industries liable for the harm they cause.

 “Break the chain of TB transmission and protect all people from tobacco use,” emphasises Dr Bam.

 Science has proven that it is critically important to screen everyone in high TB burden settings (not just those with symptoms) for TB with WHO recommended tools and offer them upfront molecular testing and linkage to treatment, care and support. Not doing so is among the factors responsible for decades of failure in TB response.

Same goes for tobacco control. No one needs to suffer from diseases caused by tobacco use or die of them. Not implementing tobacco control policies effectively and protecting everyone from tobacco use worldwide is another major failure.


Shobha Shukla – CNS

(Shobha Shukla is a feminist, health and development justice advocate, and an award-winning founding Managing Editor and Executive Director of CNS (Citizen News Service). She was also the Lead Discussant for SDG-3 at United Nations inter-governmental High Level Political Forum (HLPF 2025). She is a former senior Physics faculty of prestigious Loreto Convent College; current President of Asia Pacific Regional Media Alliance for Health, Gender and Development Justice (APCAT Media); Chairperson of Global AMR Media Alliance (GAMA received AMR One Health Emerging Leaders and Outstanding Talents Award 2024); and Host of SHE & Rights (Sexual Health with Equity & Rights). Follow her on Twitter/X @shobha1shukla or read her writings here www.bit.ly/ShobhaShukla)

@Shobha1Shukla, @CNS_Health

Zimbabwe and Cambodia getting return on investment by addressing AMR

Right to health is a fundamental human right. There is no doubt that everyone – without any exception or exclusion – should be able to live healthily in a rights-based manner – everywhere. Along with ensuring high to health is a reality for all, it is also important to recognise health financing as a smart investment.

 One important example is how one of the top threats to global health and food safety and security have been addressed in the past few years. We are referring to antimicrobial resistance (AMR) or drug resistance, which is fuelled by misuse and overuse of medicines. Because of AMR, disease-causing bacteria, virus, fungi and/or parasite become resistant to the medicine (due to inappropriate use of medicine) – and therefore, these medicines become ineffective.

 Misuse and overuse of antimicrobial medicines is rampant in human health, animal health and livestock, food and agriculture – and also polluting our environment.

 So, to address AMR, we need a multi-sectoral response that prevents it in all the sectors where inappropriate use of medicines is happening.

 That is why, global agencies on these sectors, the World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO), United Nations Environment Programme (UNEP) and World Organisation for Animal Health (WOAH) joined hands – now known as Quadripartite Joint Secretariat on AMR.

 “Addressing AMR requires urgent, coordinated action and sustained commitment from governments and diverse sectors across the One Health spectrum,” said Dr Jean-Pierre Nyemazi, Director of the Quadripartite Joint Secretariat on AMR.

 9 in 10 countries with national AMR action plans have NO financing to implement them

 Over 90% of the countries came up with their national AMR action plans globally. But only 1 in 10 countries are fully implementing these plans with monitoring and financing in place. For 9 in 10 countries with national AMR action plans, financial crunch has paralysed them from addressing one of the top global health threats using One Health approach.

World leaders at the 2024 UN General Assembly High Level Meeting on AMR had adopted a Political Declaration – one of the promises of which is to ensure that at least 60% of the countries must have fully funded national AMR action plans and implementing them by 2030.” Currently, only 11% of the countries have national AMR action plans with financing in place.

But, where domestic health financing is not adequate, who will fund a multi-sectoral and inter-ministerial national AMR action plan?

 AMR Multi-Partner Trust Fund came to life in 2019

 One option that came to life since 2019 to help low- and middle-income countries to seek financing to implement their national AMR action plans, based on One Health approach, was AMR Multi-Partner Trust Fund of the UN. It was established with an initial US$ 5 million funding from the Netherlands in 2019 so that governments could implement their national AMR action plans where needed in low- and middle-income countries.

 Dr Nyemazi who leads the Quadripartite AMR agencies said in the 5th Annual Global Media Forum on Antimicrobial Resistance: “For us to reach that goal (at least 60% of countries to have fully funded national AMR action plans and implementing them by 2030), governments also committed to mobilise at least US$ 100 million by 2030, including through AMR Multi-Partner Trust Fund (AMR MPTF) and other mechanisms. This is a powerful signal that the world understands the urgency and shared responsibility. However, technical solutions alone won’t win this fight. We need a shared responsibility.”

 AMR MPTF is the world’s principal pooled-financing mechanism specifically to support low- and middle-income countries implement and strengthen multisectoral AMR National Action Plans.

 World AMR Awareness Week (WAAW 2025) observed globally every year during 18-24 November is another reminder for richer governments to fully replenish the fund for global health security.

 We cannot afford to lose the gains made in addressing compelling health challenges

 “The gains made in AMR policy development, risk stalling without the means to act,” said Dr Emmanuel Kabali, AMR Project Coordinator, Food and Agriculture Organization of the UN (FAO).

 The AMR MPTF uniquely harnesses the expertise of the AMR Quadripartite agencies to advance country-led actions across human, animal, plant, and environmental sectors. It is breaking silos because it blends high-level global governance, surveillance, and policy with collaborative local action by leveraging knowledge and coordinating efforts of resource partners, governments, community-based organisations, and other sectors. AMR MPTF is bridging and filling gaps.

 AMR MPTF saving lives and reducing economic loss in Zimbabwe

 Thanks to AMR MPTF, Zimbabwe revived domestic production of the BOLVAC vaccine to combat tick-borne disease (in cattle etc), reducing antibiotic misuse and linking the AMR response to high-priority livestock sector issues, ensuring sustainability, shared Dr Tapfumanei Mashe, AMR Project Coordinator, WHO Zimbabwe. “Zimbabwe is an agricultural economy. So, with initiatives like BOLVAC vaccine we are not merely addressing antimicrobial resistance but also addressing the economic loss it was causing.”

 “There are a lot of scientific studies to show impact of expanded vaccination programmes and improved water, sanitation and hygiene in addressing AMR effectively – we can avert 750,000 deaths occurring due to AMR every year in low- and middle-income countries (LMICs) with such proven approaches,” said Dr Mashe.

 “In 2019, Zimbabwe also introduced typhoid conjugate vaccine (TCV) to prevent typhoid fever caused by bacteria Salmonella typhi. Typhoid fever was also a cause of increasing AMR. Using AMR MPTF resources we are tracking impact of introducing TCV. We saw a reduction in incidence of typhoid fever from 1373 per 100,000 before introduction of TCV vaccine to 341 per 100,000 after the introduction of TCV vaccine. This has also resulted in reduction of AMR,” said Dr Mashe.

 “By introducing typhoid conjugate vaccine, we are not merely addressing AMR but also addressing healthcare of the people and reducing costs which the government was incurring for those with typhoid. In 2018, the first-line medicine for typhoid (ciprofloxacin) was not working because of drug resistance, so we had to treat with azithromycin which was more expensive. So, typhoid conjugate vaccine has not only reduced AMR but also reduced the expenditure for government as well as mortality and morbidity for the people,” said Dr Mashe.

 “As a result of multi-sectoral team working together, we have strengthened surveillance, where we are tracking antimicrobial resistance in different sectors, including human health, animal health, environment and food and agriculture. Quality of medicine is another important area to focus on for us in Zimbabwe. Thanks to AMR MPTF, Zimbabwe is also tracking phosphide resistance by setting up a surveillance system where we can check the prevalence of fortified medicines circulating in the country,” added Dr Mashe.

 Cambodia had ambition but no means: MPTF enabled it to go the One Health way

 In 2019, Cambodia had a multi-sectoral national AMR action plan but hardly any finances to implement it. AMR MPTF funding not only enabled it to implement the plan but also transition from AMR inter-ministerial committee towards a broader One Health governance framework.

 “Without enough financial resources, before MPTF funding, Cambodia’s efforts to implement AMR National Action Plan were very fragmented. When MPTF funding came to Cambodia, we were able to significantly step up the implementation of Cambodia’s National Action Plan on AMR. Resourced by MPTF, we established Cambodia’s national multi-sectoral coordination body based on the One Health approach. It brought together different agencies in sectors like human health, animal health and livestock, food and agriculture, and environment,” said Dr Makara Hak, Adviser on Animal Health, FAO (Food and Agriculture Organization of the United Nations), Cambodia. “Thanks to MPTF support, different committee meetings were convened regularly to review policy regulations to guide implementation of Cambodia’s AMR National Action Plan – something which could never happen in the past.”

 “Cambodia could also accelerate its capacity building efforts at national as well as sub-national levels to address AMR. Over 200 provincial and district veterinarians and over 1000 village animal health workers in the private sector have been trained as per the AMR treatment guidelines. All this could happen due to the support of MPTF,” confirmed Dr Mak.

 “Thanks to MPTF, Cambodia could invest in strengthening animal health laboratories which is very important for addressing AMR as well as for AMR surveillance systems. Cambodia introduced Laboratory Information Management System to ensure that data meets international standards. We also invested in building the capacity of the academia and laboratories (including fishery laboratories) as part of Animal Health Laboratory Network,” said Dr Mak.

 “This progress in Cambodia has unlocked new opportunities to further strengthen AMR response. We received US$ 1 million from AMR MPTF to strengthen Cambodia’s capacity which enabled us to secure another US$ 34 million for AMR and One Health in Cambodia through German Development Bank (KfW). Now, we can not only sustain these efforts but also further build upon them,” he said.

 Cambodia recently endorsed the 2nd phase of AMR multi-sectoral action plan 2025-2030. We are going to develop additional legally binding policy document to strengthen and reinforce antimicrobial use in animal health sector,” added Dr Mak.

 MPTF protecting livelihoods and safeguarding medicines we depend upon

 “Through the AMR multi-partner trust fund, low- and middle-income countries are building surveillance systems, strengthening laboratory capacity, improving infection prevention and control, and promoting responsible use of antimicrobials in human, animal and plant health. These initiatives are not abstract. They save lives. They protect livelihoods and they safeguard medicines we depend upon,” said Professor Ernst Kuipers, Global Leaders Group on AMR (GLG) member, and Former Minister of Health, Welfare and Sport, Netherlands.

 “If we act decisively now, we can preserve the effectiveness of lifesaving medicines for generations to come. If we however delay, we risk losing the very tools that make modern healthcare possible,” concluded Prof Kuipers.

 Investing in AMR MPTF is smart

 “The European Commission supports and invests in the AMR MPTF because it ensures donor coordination. It avoids duplication and fragmentation, and it gives the beneficiary countries the flexibility to focus on their priorities and their needs. And it also strengthens the One Health response by aligning all the relevant sectors,” said Dr Gunilla Eklund, the European Commission’s Directorate-General for Health & Food Safety (DG SANTE), European Commission.

 “MPTF is more than just a fund – it is a platform for partnership. And as such, we believe it is a smarter model for aid. It allows collective action to deliver more than what isolated projects would have done by themselves. And in these times, I think we cannot emphasize enough the importance of pooling resources in the current climate of tight budgets. The MPTF is a tried and a trusted mechanism that is efficient and effective. It ensures that the investments align, with the country needs and the country’s own priorities,” added Dr Eklund.


Shobha Shukla, Bobby Ramakant – CNS

(Shobha Shukla is the founding Managing Editor of CNS (Citizen News Service) and Bobby Ramakant works as CNS Health Editor. Both are on the boards of Global Antimicrobial Resistance Media Alliance (GAMA) and Asia Pacific Media Alliance for Health, Gender and Development Justice (APCAT Media). Follow them on Twitter/X: @Shobha1Shukla, @BobbyRamakant, @CNS_Health

Amidst anti-gender push, hope pins on ICFP 2025 to shift gears towards SRHRJ for all

Despite right to health and gender equality being fundamental human rights, the world is off the track from delivering on these goals in next 62 months (by 2030). Anti-rights and anti-gender pushbacks have made the situation even more grim. Activists are pinning hope on an upcoming global meet to galvanise a stronger and equitable response to deliver on these goals. 

World’s largest meet on sexual and reproductive health, rights and justice (SRHRJ) would open in next two weeks in Colombia on the theme: Equity through action, advancing SRHRJ for all. Formally called the International Conference on Family Planning or #ICFP2025, this meet also marks 30 years since Beijing Declaration and its Platform for Action were adopted in 1995.

80th United Nations General Assembly High-Level Meeting was held last month to commemorate the 30th anniversary of the 4th World Conference on Women (where Beijing Declaration 1995 was adopted along with its Platform for Action).

“The Beijing Declaration and Platform for Action is the most ambitious global political commitment on women’s rights ever achieved. It affirmed that the rights of women and girls are not separate, secondary, or negotiable – they are human rights. It has helped to power advances in some critical areas — legal protection, political participation, education, maternal mortality, recognizing the need to tackle violence against women as a global priority, and more. But progress has been slow and uneven, and no nation has achieved full equality for women and girls and gender diverse peoples,” said Shobha Shukla, Host of SHE & Rights (Sexual Health with Equity & Rights) and Lead Discussant for SDG-3 at the United Nations High Level Political Forum (HLPF 2025).

Separating signal from the noise

“International Conference on Family Planning (ICFP 2025) has received a record number of 5174 abstract submissions – highest-ever in its history. This means that there were many more ideas competing for attention. Bigger responsibility was for the organisers and different ICFP committees to separate the signal from noise itself. There are signals emerging across the scientific programme and community agenda from the ICFP 2025. For example, you will see there are topics around climate SRHRJ popping up everywhere and from the heat supply chains or displacements to financing, resilience, shrinking civic spaces, among others. Topics like youth leadership has moved into the core ICFP 2025 programme. There are a lot of youth-focused sessions including a youth pre-conference which is 100% led by the young people from all over the world. Youth sub-committee meetings have taken place every month in the lead up to ICFP 2025,” said Dina Chaerani, Host of Sex O’Clock News, Family Planning News Network (FPNN) and YIELD Hub.

“There are many more pre-conferences happening around ICFP 2025. For example, on youth, comprehensive sexuality education, and other issues,” said Dina.

SRHRJ trends turning into actual practices

“ICFP 2025 is doubling up on the accessibility. There are plenary sessions, ICFP Live stage sessions, and select high impact sessions will be live streamed on YouTube as well and recorded to an online library, so people that cannot be there physically can also watch them online or virtually. If you want deep technical dives into ICFP 2025 programme, then there is a paid virtual scientific stream as well,” added Dina.

Dina was one of the keynote speakers for SHE & Rights session held ahead of International Conference on Family Planning (ICFP 2025) on the theme: “It is time for accountability and action after UNGA High Level Meeting around Beijing+30.”

80th UNGA saw progress but also pushbacks

At 80th UN General Assembly this year, there were attempts made by USA to “torpedo” gender equality and human right to health. USA government categorically said at UN High Level Meeting on Non-Communicable Diseases and Mental Health (on 25th September 2025) that it does not recognise “constitutional or international right to abortion.”

However, at the United Nations Economic and Social Council, decision to revitalise United Nations Commission on the Status of Women (CSW) was adopted by consensus, which gives hope. It was also decided that first United Nations High Level Meeting on ending violence against women and girls would be held at 70th UN Commission on the Status of Women (CSW70) in 2026.

“CSW revitalisation process is an effort by the UN to strengthen the mandate of the UN Commission on the Status of Women (CSW). We put out an advocacy brief that made 3 clear demands,” said Shiphrah Belonguel, Global Advocacy Officer, Fòs Feminista (International Alliance for Sexual and Reproductive Health, Rights and Justice – SRHRJ). Fos Feminista also serves as co-convener of Women’s Rights Caucus (WRC), a global self-organised feminist space that engages with CSW process.

Shiphrah lists out the 3 key asks:

1. Defending and strengthening the mandate of the CSW as a robust normative platform for gender equality.

2. Ensuring that the agreed conclusions that come out of the process remain a central and ambitious normative framework, reaffirming member states’ commitments to the Beijing Declaration and its Platform for Action, and

3. Safeguarding civil society participation and preventing any rollback of civic space.

“So, demand-3 has been a particularly contentious point of advocacy especially with several member states who have pushed back against institutionalising practices related to civil society participation, such as the civil society town hall. Since our collective advocacy, the revitalisation resolution has already been adopted within the framework of the UN Economic and Social Council (ECOSOC),” said Shiphrah.

Women’s rights, bodily autonomy and SRHRJ are not negotiable

“It is also important to contextualise all of this – like all of these processes that are happening in the UN helps us understand how governments are pushing gender equality. We have seen that during the UN High Level Meeting, some are twisting gender equality language to push for more pronatalist agenda framing women’s lives only through the lens of fertility and population. And we know that’s deeply dangerous,” added Shiphrah.

“When we get to ICFP 2025, we need to be clear. We need to come together as a community and really think through and about how family planning is being tied to ‘panic around fertility crisis’ or demographic panics. We have to insist as a community of SRHRJ advocates that women’s rights, bodily autonomy and reproductive justice are not negotiable – and they will always be integral to any family planning programming and activities,” rightly added Shiphrah. “For now, our priority is to keep feminist movements inside these processes and monitoring them and disrupting as necessary, making sure that UN reform does not hollow out civil society space and does not sideline gender and human rights, but elevates them.”

SHE & Rights session was together hosted by Global Center for Health Diplomacy and Inclusion (CeHDI), International Conference on Family Planning (ICFP) 2025, Y-PEER Asia Pacific, Y-PEER Laos, Family Planning News Network (FPNN), International Planned Parenthood Federation (IPPF), Asian-Pacific Resource and Research Centre for Women (ARROW), Women’s Global Network for Reproductive Rights (WGNRR), Asia Pacific Media Alliance for Health and Development (APCAT Media) and CNS.

Despite promises made by all the governments to deliver on gender equality and right to health, progress remains patchy and sketchy – and fragile – at best. We need to walk the talk on commitments enshrined on so many UN legally binding treaties, agreements, declarations and other instruments along with the UN Charter.


Shobha Shukla – CNS

(Shobha Shukla is a feminist, health and development justice advocate, and an award-winning founding Managing Editor and Executive Director of CNS (Citizen News Service). She was also the Lead Discussant for SDG-3 at United Nations inter-governmental High Level Political Forum (HLPF 2025). She is a former senior Physics faculty of prestigious Loreto Convent College; current President of Asia Pacific Regional Media Alliance for Health, Gender and Development Justice (APCAT Media); Chairperson of Global AMR Media Alliance (GAMA received AMR One Health Emerging Leaders and Outstanding Talents Award 2024); and Host of SHE & Rights (Sexual Health with Equity & Rights). Follow her on Twitter/X @shobha1shukla or read her writings here www.bit.ly/ShobhaShukla)

@Shobha1Shukla, @CNS_Health

Epistaxis

The Health Thread Favicon

Written By THT Editorial Team

Dr. Chetana Pathak

Reviewed by Dr. Chetana Pathak, Otorhinolaryngologist/Head & Neck Surgeon, MBBS, MS(Otorhinolaryngology), 

Nosebleeds, or epistaxis, are a common medical issue affecting approximately 60% of people in the United States at some point in their lives. Although most episodes are minor and self-limiting, around 6% of individuals experiencing nosebleeds will seek medical attention (Tunkel et al., 2020). In children, epistaxis is particularly prevalent, with 75% having at least one episode (Tunkel et al., 2020). There are two primary types of nosebleeds: anterior, which is more common, and posterior, which, although less frequent, often require medical intervention (Tabassom & Dahlstrom, 2024).

Epistaxis, despite often being seen as a mere nuisance, can occasionally pose life-threatening risks, particularly in resource-limited settings where adequate healthcare facilities are scarce. It is estimated that 60% of the global population will experience epistaxis, with about 6% requiring medical treatment due to the ineffectiveness of home remedies (Adoga et al., 2019).

Causes of Epistaxis

The most common cause of epistaxis are idiopathic (38.09%) followed by hypertension (27.38%), trauma (15.47%), and coagulopathy (8.33%) (Parajuli R, 2015)

Other Local causes are:

Anatomic deformities

Intranasal tumors

Low humidity

Vigorous nose blowing

Nose picking

In adults, medications such as non-steroidal anti-inflammatory drugs (NSAIDs) and anticoagulants like heparin and warfarin are common contributors. Hereditary bleeding disorders, including hemophilia A, hemophilia B, and von Willebrand disease, are also associated with epistaxis (Ameya et al., 2021).

Additionally, chronic vascular damage related to hypertension has been suggested as a potential mechanism linking high blood pressure to nosebleeds (Byun et al., 2021).

Management and Treatment of Epistaxis

Following steps can be used at Home. This method is also called Hippocratic method

  1. Sit upright and lean slightly forward to prevent blood from running down your throat, which can cause nausea, vomiting, and diarrhea. Avoid lying flat or tilting your head back.
  2. Breathe through your mouth.
  3. Use a tissue or damp washcloth to catch the blood.
  4. Pinch the soft part of your nose with your thumb and index finger, pressing it against the hard bony ridge that forms the bridge of your nose. Pinching above or on the bony part won’t effectively stop the bleeding.
  5. Maintain pressure on your nose for at least five minutes before checking if the bleeding has stopped. If it persists, continue pinching for another 10 minutes.
  6. Optionally, apply an ice pack to the bridge of your nose to help constrict blood vessels and provide comfort. This step is not essential but can be helpful (Cleveland Clinic).

Managing epistaxis requires a thorough examination and detailed patient history to identify the bleeding site and cause. Treatment methods vary depending on the location, severity, and etiology of the bleeding and can be broadly categorized into nonsurgical and surgical approaches. Simple measures include pinching the nose, while more severe cases might require ligation of vessels (Parajuli, 2015).

The majority of nosebleeds are acute, sporadic, and self-limited, typically responding to simple compression but sometimes requiring more aggressive measures like cautery (can be chemical or electric) or nasal packing. Conventional gauze pack and Merocel nasal pack are the common pack used in refractory anterior epistaxis (Shanmugam et.al, 2019)

Vasoconstrictors, such as oxymetazoline, xylometazoline can help locate the bleeding site. If simple measures fail, tranexamic acid, nasal cautery with silver nitrate, or nasal packing may be necessary. (Director, Paediatric Emergency Department, 2023). Endoscopic ligation of the sphenopalatine artery is done in case of persistent bleeding (Snyderman & Carrau, 1997).

If there is persistent bleeding then endoscopic ligation of the bleeding vessel is done.

  • SPA ligation has been reported to be effective in 87-92% of cases (Kishimoto 2018, Wormald 2000).
  • Bilateral SPA ligation has been shown to have lower rebleeding rates compared to unilateral ligation (Hervochon 2018).
  • SPA ligation may reduce the risk of future severe epistaxis in anticoagulated patients.

REFERENCES

  1. Tunkel, D. E., Anne, S., Payne, S. C., et al. (2020). Clinical Practice Guideline: Nosebleed (Epistaxis). ss 162(1_suppl), S1-S38. https://doi.org/10.1177/0194599819890327
  2. Tabassom, A., & Dahlstrom, J. J. (2024). Epistaxis. In StatPearls. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK435997/
  3. Adoga, A. A., Kokong, D. D., Mugu, J. G., Okwori, E. T., & Yaro, J. P. (2019). Epistaxis: The demographics, etiology, management, and predictors of outcome in Jos, North-Central Nigeria. Annals of African Medicine, 18(2), 75-79. https://doi.org/10.4103/aam.aam_24_18
  4. Ameya, G., Biresaw, G., Mohammed, H., Chebud, A., Meskele, M., Hussein, M., & Endris, M. (2021). Epistaxis and Its Associated Factors Among Precollege Students in Southern Ethiopia. Journal of Blood Medicine, 12, 1-8. https://doi.org/10.2147/JBM.S309273
  5. Byun, H., Chung, J. H., Lee, S. H., Ryu, J., Kim, C., & Shin, J. (2021). Association of Hypertension with the Risk and Severity of Epistaxis. JAMA Otolaryngology–Head & Neck Surgery, 147(1), 34-40. https://doi.org/10.1001/jamaoto.2020.2906
  6. Parajuli, R. (2015). Evaluation of Etiology and Treatment Methods for Epistaxis: A Review at a Tertiary Care Hospital in Central Nepal. International Journal of Otolaryngology, 2015, 283854. https://doi.org/10.1155/2015/283854
  7. https://my.clevelandclinic.org/health/diseases/13464-nosebleed-epistaxis
  8. Director, Paediatric Emergency Department. (2023). Emergency department management of epistaxis (Document ID CHQ-GDL-07450, Version 2.0). Executive Director Medical Services. https://my.clevelandclinic.org/health/diseases/13464-nosebleed-epistaxis
  9. Shanmugam, V. U., PremNivas, P., Swaminathan, B., Shanmugan, R., & Suji, S. (2019). A comparison of conventional nasal pack with Merocel nasal pack in the management of epistaxis. Journal of Medical Science and Clinical Research, 7(10). https://dx.doi.org/10.18535/jmscr/v7i10.156
  10. Carl H. Snyderman, Ricardo L. Carrau, Endoscopic ligation of the sphenopalatine artery for epistaxis, Operative Techniques in Otolaryngology-Head and Neck Surgery, Volume 8, Issue 2,1997, Pages 85-89, ISSN 1043 1810, https://doi.org/10.1016/S1043-1810(97)80007-3.

Exploring the Role of Metabolic Psychiatry in Understanding Mental Health Disorders

The Health Thread Favicon

Written By THT Editorial Team

Dr. Kamal Gautam

Reviewed by Dr. Kamal Gautam, MBBS(KU), MD Psych (IOM), Currently working at Transcultural Psychological Organization Nepal (TPO Nepal)

Introduction:

Metabolic psychiatry is an emerging field that investigates the bidirectional relationship between metabolic dysregulation and psychiatric disorders. Increasing evidence suggests that disturbances in metabolism, including alterations in glucose metabolism, lipid metabolism, and hormonal imbalances, may contribute to the pathophysiology of various mental health conditions. This research article aims to explore the latest findings and concepts in metabolic psychiatry, highlighting the potential implications for understanding and managing psychiatric disorders.

Metabolism and Mental Health:

Traditionally, mental health disorders have been primarily viewed as disorders of the brain, focusing on neurotransmitter imbalances and neuronal dysfunction. However, emerging research indicates that disturbances in metabolism can impact brain function and significantly contribute to psychiatric symptoms. Metabolic abnormalities, such as insulin resistance, inflammation, oxidative stress, and mitochondrial dysfunction, have been observed in individuals with depression, anxiety, bipolar disorder, schizophrenia, and other mental health conditions.

Insulin Resistance and Depression:

Insulin resistance, a condition characterized by impaired cellular response to insulin, has been associated with an increased risk of depression. Studies have demonstrated that insulin resistance disrupts neuronal signaling pathways, affects neurotransmitter metabolism, and promotes neuroinflammation, all of which may contribute to the development and persistence of depressive symptoms. A longitudinal study by Timonen et al. (2005) found that insulin resistance predicted the onset of depressive symptoms in middle-aged individuals.

The global prevalence of type 2 diabetes is on the rise. Within the diabetic population, approximately 30% experience comorbid mental health issues, such as depression, schizophrenia, delirium, and substance misuse, including tobacco smoking. Interestingly, there is evidence suggesting a bidirectional relationship between these mental disorders and diabetes. Moreover, the prevalence of depression and anxiety among individuals with diabetes exceeds that of the general population, with a striking 50-100% heightened risk of depression in diabetic patients. Presently, psychiatrists recognize the interplay between psychiatric disorders and medical conditions, acknowledging that they often influence each other (Al-Atram AA. ,2018).

Dyslipidemia and Bipolar Disorder:

Dyslipidemia, characterized by abnormal levels of lipids (e.g., cholesterol and triglycerides) in the bloodstream, has been implicated in bipolar disorder. Altered lipid metabolism can influence membrane composition and fluidity, affecting neuronal signaling and synaptic function. Several studies have reported associations between dyslipidemia and bipolar disorder, including altered lipid profiles in individuals with the disorder Fagiolini et al. (2014) found that patients with bipolar disorder had significantly higher levels of triglycerides and lower levels of high-density lipoprotein (HDL) cholesterol compared to healthy controls.

Depression stands as one of the most prevalent psychiatric disorders among adults, posing a significant public health concern in the United States. Mounting evidence suggests a correlation between depression and heightened risks of diabetes and cardiovascular diseases (CVD).

Metabolic syndrome (MetS), comprising various CVD risk factors like central obesity, hyperglycemia, elevated blood pressure, hypertriglyceridemia, and reduced HDL cholesterol, is widespread in the general populace and is linked to increased susceptibility to diabetes and CVD. Given the substantial public health burdens posed by both depression and MetS, recent focus has been directed towards understanding the relationship between these two conditions (Pan et.al,2012)

Hormonal Imbalances and Schizophrenia:

Hormonal imbalances, particularly involving the hypothalamic-pituitary-adrenal (HPA) axis and sex hormones, have been implicated in the pathophysiology of schizophrenia. Dysregulation of the HPA axis, characterized by abnormal cortisol levels and stress response, is frequently observed in individuals with schizophrenia. Moreover, alterations in sex hormone levels, such as estrogen and testosterone, have been associated with symptom severity and cognitive impairments in schizophrenia. A study by Riecher-Rössler et al. (2018) demonstrated that estrogen treatment improved symptoms and cognition in postmenopausal women with schizophrenia.

Conclusion:

Metabolic psychiatry offers a novel perspective on the etiology and treatment of psychiatric disorders by exploring the interplay between metabolic dysregulation and mental health conditions. The emerging evidence supports the concept that disturbances in metabolism can contribute to the pathophysiology of depression, bipolar disorder, schizophrenia, and other psychiatric disorders. Understanding the role of metabolic factors in mental health opens new avenues for developing targeted interventions, such as lifestyle modifications, dietary interventions, and pharmacological approaches that address metabolic dysfunctions alongside traditional psychiatric treatments.

Further research is needed to elucidate the complex mechanisms underlying the relationship between metabolism and mental health and to identify potential therapeutic targets. Integrating metabolic assessments and interventions into psychiatric practice holds promise for personalized approaches and improved outcomes in the management of mental health disorders.

REFERENCES

  1. Timonen M, et al. Insulin resistance and depressive symptoms in young adult males: Findings from Finnish military conscripts. Psychosom Med. 2005;67(5): 853-857.
  2. Fagiolini A, et al. Dyslipidemia in bipolar disorder: Causes and consequences. Curr Psychiatry Rep. 2014;16(10): 1-9.
  3. Riecher-Rössler A, et al. The effects of estradiol on cognition and symptoms in schizophrenia. Am J Psychiatry. 2018;175(3): 225-233.
  4. Al-Atram AA. A review of the bidirectional relationship between psychiatric disorders and diabetes mellitus. Neurosciences (Riyadh). 2018 Apr;23(2):91-96. doi: 10.17712/nsj.2018.2.20170132. PMID: 29664448; PMCID: PMC8015449
  5. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, Hu FB. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care. 2012 May;35(5):1171-80. doi: 10.2337/dc11-2055. PMID: 22517938; PMCID: PMC3329841

    Is Your Medicine Cabinet Missing This? Laughter’s Amazing Benefits

    Written by Liza Nagarkoti , BSc Nursing, MA(Nutrition), Project Officer (Health) LWF Nepal

    A robust sense of humor isn’t merely a pleasant diversion during challenging times; it’s a valuable asset in our pursuit of overall well-being. When we find ourselves amused by a friend’s witty remark or a comedian’s act, the positive impacts of humor resonate through our bodies, minds, and social connections. It’s more than just entertainment; it contributes to enhancing our physical, mental, and emotional health.

    According to Dattilo, an instructor of psychology at Harvard Medical School, humor’s psychological benefits are immediate, lifting mood and reducing stress and anxiety, while also affecting us physically by reducing cortisol levels and increasing dopamine and serotonin neurotransmitters (Harvard Gazette, 2023).

    Research has shown that laughter’s health benefits are extensive, including pain relief, increased happiness, and enhanced immunity. Positive psychology recognizes laughter and a sense of humor as one of the 24 main signature strengths (Verywell Mind).

    The physical benefits of laughter are diverse:

    • Laughter boosts heart and respiratory rates and oxygen consumption temporarily, leading to subsequent relaxation. While it’s not equivalent to aerobic exercise, it still offers physical benefits. Laughing for 10-15 minutes daily can burn an additional 10-40 calories.
    • It positively impacts heart function by increasing stroke volume, cardiac output, and dilating blood vessels.
    • Intense laughter enhances muscle tone.
    • Watching funny videos stimulates the sympathetic nervous system (SNS) without raising blood pressure.
    • Laughter reduces cortisol levels, the stress hormone.
    • It activates the brain’s mesolimbic dopaminergic reward system.
    • Laughing boosts levels of serum immunoglobulins A and E and tends to increase natural killer cell activity.
    • It raises levels of beta-endorphins, the body’s feel-good chemicals, and increases human growth hormone (U.S. Department of Veterans Affairs).

    Relationship between Laughter and Mental Health

    The relationship between laughter and mental health is profound. It interrupts distressing emotions, promoting relaxation, stress reduction, increased energy, focus, and productivity. Additionally, laughter fosters a more positive perspective on situations, creating psychological distance and diffusing conflict. It also strengthens social bonds, which can profoundly impact mental and emotional well-being (HelpGuide).

    In conclusion, laughter emerges as a potent medicine for holistic health, offering a multitude of benefits across physical, psychological, and social dimensions

    REFERENCES

    1. Harvard Gazette. (2023, January). A laugh a day keeps the doctor away. Retrieved from https://news.harvard.edu/gazette/story/2023/01/a-laugh-a-day-keeps-the-doctor-away/
    2. Verywell Mind. (n.d.). The Stress Management and Health Benefits of Laughter. Retrieved from https://www.verywellmind.com/the-stress-management-and-health-benefits-of-laughter-3145084
    3. S. Department of Veterans Affairs. (n.d.). Healing Benefits: Humor & Laughter. Retrieved from https://www.va.gov/WHOLEHEALTHLIBRARY/tools/healing-benefits-humor-laughter.asp
    4. (n.d.). Laughter is the Best Medicine. Retrieved from https://www.helpguide.org/articles/mental-health/laughter-is-the-best-medicine.htm

    Advancing Kidney Health: Transforming Innovative Concepts into Practical Solutions

    The Health Thread Favicon

    Written By THT Editorial Team

    Dr. Nabin Bahadur Basnet

    Reviewed by Dr. Nabin Bahadur Basnet, Consultant Interventional Nephrologist, MBBS, PhD, FISN

    Exploring effective treatment options for end-stage renal disease (ESRD) has led to the development of innovative technologies such as implantable bio artificial kidneys (BAK) and kidney regeneration. These advancements are not just impressive achievements; they are sources of hope for millions around the globe.

    Implantable Bio artificial Kidney (BAK): A Game Changer

    Imagine a kidney replacement that’s like having a tiny, high-tech sidekick doing all the hard work for you. That’s the dream behind the implantable BAK. Dr. William H. Fissell and Shuvo Roy, Ph.D., are the masterminds behind this marvel. Picture a device no bigger than a soda can, but with the power to mimic your kidney’s functions. It hooks up to your blood vessels, acting like a natural kidney without the hassle of dialysis or meds.

    The Kidney Project: Making Sci-Fi a Reality

    The Kidney Project, a tag team effort between Vanderbilt University Medical Center and the University of California San Francisco, has been the driving force behind the BAK’s evolution. Their latest prototype is a real showstopper. It’s proven it can keep kidney cells alive inside a bioreactor, essentially acting as a mini kidney. The silicon membranes protect these cells like armor, ensuring they keep ticking away. (Kim et al., 2023)

    Preclinical Success and What’s Next

    Recent trials have been a roaring success. The BAK operates silently in the background, much like a superhero, without setting off alarms in the recipient’s immune system. This means it could be the ticket to freedom from dialysis and the endless wait for donor kidneys. . (Kim et al., 2023)

    Kidney Regeneration Tech: Healing Magic

    But wait, there’s more! While the BAK steals the spotlight, kidney regeneration tech is quietly making waves. Scientists have stumbled upon a magic trick: block a pesky protein called interleukin-11 (IL-11), and damaged kidney cells start to regrow. It’s like hitting the rewind button on kidney damage caused by diseases or injuries. (Widjaja et al., 2022)

    The Future’s Bright for Kidney Care

    Combine the power of BAK with regeneration tech, and you’ve got a winning combo. The BAK offers immediate relief for those in dire need, while regenerative therapies work their magic over time, restoring natural kidney function.

    Challenges and the Big Picture

    Sure, these innovations are thrilling, but there are hurdles to jump. We need to make sure the BAK is safe and effective for humans and fine-tune regeneration therapies. Plus, we can’t forget about making these treatments accessible and affordable for everyone.

    In Conclusion: Hope on the Horizon

    The birth of the BAK and kidney regeneration tech is like finding a pot of gold at the end of the rainbow for kidney disease sufferers. These breakthroughs promise a brighter future, where kidney failure isn’t a life sentence. It’s a journey filled with obstacles, but the destination—a world free from the grip of kidney disease—is within reach.

    REFERENCES

    1. Kim, E. J., Chen, C., Gologorsky, R., Santandreu, A., Torres, A., Wright, N., Moyer, J., Chui, B. W., Blaha, C., Brakeman, P., Vartanian, S., & Tang, Q. (2023, August 29). Can an Artificial Kidney Finally Free Patients from Dialysis? UCSF. Retrieved from UCSF News
    2. Widjaja, A. A., Viswanathan, S., Shekeran, S. G., Adami, E., Lim, W. W., Chothani, S., Tan, J., Goh, J. W. T., Chen, H. M., Lim, S. Y., Boustany-Kari, C. M., Hawkins, J., Petretto, E., Hübner, N., Schafer, S., Coffman, T. M., & Cook, S. A. (2022). Targeting endogenous kidney regeneration using anti-IL11 therapy in acute and chronic models of kidney disease. Nature Communications, 13(1), 7497. https://doi.org/10.1038/s41467-022-35306-1

    A hope for spinal cord injury

    The Health Thread Favicon

    Written By THT Editorial Team

    Dr Aayush Shrestha

    Reviewed by Dr. Aayush Shrestha, Orthopaedic & Spine Surgeon, MS Ortho, FSS 

    Spinal cord injury (SCI) is a devastating condition that can cause permanent loss of function and affect mobility, senses, and many other bodily functions.Globally 15 million people are living with SCI with the majority of cases due to preventable trauma ( WHO,2024). Beyond the physical limitations, SCI also has a profound impact on the psychological well- being of individuals. Adults living with SCI have a significantly raising risk of depression and anxiety (Peterson et al., 2022). Furthermore, SCI imposes a substantial financial burden on society. The estimated lifetime burden of  per individual with SCI ranges from 1.5 to 3.0 million due to long term care and loss of employment ( Diop, Epstein, & Gaggerro, 2021)  Despite significant advances in medical technology and rehabilitation techniques, SCI continues to face many challenges in treatment and recovery. However, recent research has revealed new approaches and treatments that may improve outcomes for patients with SCI.

    Stem Cell Therapy: Building New Pathways

    One of the most promising areas of SCI research is the use of stem cells. Stem cells are unique because they are like versatile building blocks that can become different types of cells, including the nerve cells (neurons) that make up the spinal cord. Researchers are investigating the use of different stem cell types in the treatment of SCI, with some of the most common being:

    • Mesenchymal stem cells (MSCs): These cells are found in bone marrow and can develop into several cell types, including bone, cartilage, and fat cells. In SCI research, MSCs have shown promise in promoting nerve regeneration and reducing inflammation.
    • Neural stem cells (NSCs): These stem cells are already on the path toward becoming cells of the nervous system. NSCs hold the potential to directly replace damaged neurons and help rebuild the communication pathways in the injured spinal cord.

    A recent study published in Stem Cell Reports showed that transplanting stem cells called mesenchymal stem cells (MSCs) improved the ability to move and promoted nerve regeneration in rats with SCI (Wang et al., 2021). The researchers found that MSCs helped new nerve cells grow, improved the overall health of the spinal cord, and even contributed to forming new connections across the injury site.

    Another study recently published in Nature Communications showed that transplanting neural stem cells (NSCs) improved bladder function in rats with SCI (Chen et al., 2020). The researchers found that the NSCs transformed into neurons that became part of the spinal cord circuitry, improving signaling between the bladder and the brain.

    Boosting Nerve Growth with Neurotrophic Factors

    In addition to stem cells, researchers are also investigating the use of neurotrophic factors in the treatment of SCI. Neurotrophic factors are like special “fertilizers” for nerve cells, supporting them in multiple ways:

    • Promoting Growth: They stimulate the development of new neurons and encourage the branching of nerve fibers, helping them form connections.
    • Supporting Survival: Neurotrophic factors help existing neurons stay healthy and function optimally.
    • Reducing Inflammation: Some neurotrophic factors can help calm the excessive inflammation that occurs after a spinal cord injury.

                                   

    A recent study published in the journal Nature Communications showed that administering a neurotrophic factor called brain-derived neurotrophic factor (BDNF) improved the ability to move and promoted nerve regeneration in rats with SCI (Li et al., 2021). BDNF helped new neurons grow, encouraged connections within the injured spinal cord, and improved the overall health of nerve tissue.

    Electrical Stimulation: Re-wiring the Connection

    In addition, researchers are also investigating the use of electrical stimulation in the treatment of SCI. Electrical stimulation involves the use of electrical currents to stimulate nerves and muscles. This type of stimulation is already used in other areas of medicine, such as pacemakers for the heart, and researchers are exploring how it could be adapted to help in the recovery from spinal cord injury.

    A recent study published in Scientific Reports showed that the use of electrical stimulation improved the ability to move and promoted nerve regeneration in rats with SCI (Zhang et al., 2020). The researchers believe that electrical stimulation works by encouraging surviving nerve fibers to sprout new branches, facilitating the formation of alternative signal pathways around the damaged area.

    Calming the Immune Response for Better Healing

    In addition to these treatments, researchers are also investigating the role of immune cells in SCI. SCI triggers a complex immune response within the body, and while some aspects of this response are helpful for healing in the acute phase, prolonged inflammation can actually further damage the spinal cord. Researchers are investigating ways to modulate the immune response (adjust its activity) to improve healing and reduce long-term damage.

    A recent study published in the journal Nature Neuroscience showed that targeting a type of immune cell called microglia improved motor function and nerve regeneration in mice with SCI (Zhou et al., 2021). Microglia are like the clean-up crew of the nervous system, but after injury, they can become overactive and contribute to tissue damage. This study suggests that finding ways to calm microglia activity could be a beneficial treatment strategy.

    Hope for the Future

    In summary, recent studies have identified several promising treatments for SCI, including stem cell transplantation, neurotrophic factors, electrical stimulation, and immune modulation. Although these therapies are still in development, they hold great promise for improving outcomes for patients with SCI. Further research is needed to fully understand these treatment options, optimize their delivery, and develop safe and effective treatments for SCI. 

    REFERENCES

    1. World Health Organization. (2024, April 16). Spinal cord injury. WHO. https://www.who.int/news-room/fact-sheets/detail/spinal-cord-injury
    2. Peterson, M., Meade, M., Lin, P., Kamdar, N., Rodriguez, G., Mahmoudi, E., & Krause, J. (2022, February 7). Mental health is an issue for people with spinal cord injury  Chronic pain makes it worse University of Michigan Institute for Healthcare Policy & Innovation. Retrieved from https://ihpi.umich.edu/news/mental-health-issue-people-spinal-cord-injury-chronic-pain-makes-it-worse
    3. Diop, M., Epstein, D., & Gaggero, A. (2021). Quality of life, health and social costs of patients with spinal cord injury: A systematic review. European Journal of Public Health, 31(Supplement_3), ckab165.177. https://doi.org/10.1093/eurpub/ckab165.177
    4. Wang, L., Ji, H., Zhou, J., Xiong, Y., and Zhang, Y. (2021). Mesenchymal stem cell transplantation improves motor function and promotes nerve regeneration in a rat model of spinal cord injury. Stem Cell Reports, 16(5), 1159-1174.
    5. Chen, J., Zhang, Z., Zhang, L., Li, Y., Liu, Q., Lu, D. … and Wang, L. (2020). Neural stem cell transplantation improves bladder dysfunction after spinal cord injury in rats. Nature Communication, 11(1), 1-14.
    6. Li, L., Xiao, Y., Liu, X., and Chen, J. (2021). Brain-derived neurotrophic factor rescues neuronal deficit in a rat model of spinal cord injury through PI3K/AKT signaling. Nature Communications, 12(1), 1-16.
    7. Zhang, L., Xiong, Y., Mahajan, and Ji, H. (2020). Electrical stimulation promotes functional recovery after spinal cord injury by increasing neurogenesis and inhibiting microglia-mediated inflammation. Scientific Reports, 10(1), 1-15.
    8. Zhou, K., Zhong, S., Liang, S., and Yao, F. (2021). Targeting microglia to treat neurological diseases. Nature Neuroscience, 24(4), 421-433.

     

    New research in pancreatic cancer screening

    The Health Thread Favicon

    Written By THT Editorial Team

    Dr. Asmita Pandey

    Reviewed by Dr. Asmita Rayamajhi, Consultant Oncologist, M.D.

    Pancreatic cancer is a tough and dangerous type of cancer that’s hard to treat and often doesn’t have a good outcome. But there’s good news: a group of experts from around the world is working hard to create a new program that will help doctors find this cancer early, which could save many lives.

    The group called PRECEDE is leading a project that shows how finding pancreatic cancer early could help more people survive it. Right now, not many people survive this cancer worldwide—only about 12 out of 100 do (. Rawla, Sunkara, & Gaduputi, 2019). But if it’s found early, more than 80 out of 100 could survive, especially if they can have surgery. Sadly, most people find out they have this cancer too late when it’s already spread too much. ((MUHC News, 2024)

    PRECEDE is working on a better way to keep an eye on people who are more likely to get pancreatic cancer because of their personal or family health history. Dr. George Zogopoulos and his team are focusing on how to check these high-risk people more effectively, especially if they have relatives who had pancreatic cancer or they have genes that could make them get cancer. (fortner, 2024 )

    The study shows that people who have a high chance of getting pancreatic cancer are really good at following advice on getting checked. These checks can be done well in places that specialize in health care. This proves that PRECEDE can use this method of checking for cancer all over the world and gather information to learn more and get better at watching for signs of cancer in patients. (MUHC News, 2024)

     Based on their findings, the researchers suggest putting people who might get pancreatic cancer into three groups. These groups are for people who have a family history of the disease, those who have a genetic mutation that could cause cancer, or those who have both these risk factors. If someone is worried they might be at risk for pancreatic cancer, they can join the PRECEDE program and go to one of its centers in North America or Europe to get checked and learn more about their risk.

    The study found that people who are at high risk for pancreatic cancer just because of their family history are more likely to have cysts in their pancreas than those who have a genetic change known to cause cancer but no family history. These cysts might mean that these individuals could be more likely to develop pancreatic cancer as time goes by. This could happen either because the cysts themselves change or because the cysts are a sign that the pancreas is more likely to develop problems that could turn into cancer. Zogopoulos et al., 2024)

    We need more time to watch and see if having family members with pancreatic cancer means a person is more likely to get it themselves, compared to just having a gene change that can cause cancer Zogopoulos et al., 2024). The study points out that even though it’s been hard to set up big screening programs for people at high risk of pancreatic cancer, it’s possible to do this kind of research with many centers working together across different countries. The first results from the scans in this study show that we need to keep researching how to find pancreatic cancer early. (Fortner, 2024).

    Besides other methods, artificial intelligence tools are helping a lot in the battle against pancreatic cancer. One of these programs was able to pick out the people who were most likely to get pancreatic cancer, up to three years before they were actually diagnosed, just by looking at their health records Pesheva, 2023).This big step forward in being able to predict health issues was made possible by researchers from Harvard Medical School and the University of Copenhagen working together with the VA Boston Healthcare System, Dana-Farber Cancer Institute, and the Harvard T.H. Chan School of Public Health.

    Using AI to check for pancreatic cancer could really change how we find and treat this illness. It’s a way that doesn’t hurt, doesn’t cost much, and is really good at spotting people who might have it (Huang et al., 2022). For example, AI can look very closely at CT scans and MRIs to find tiny signs of cancer that people might not notice (Katta et al., 2023). It can also help figure out if cysts in the pancreas might turn into cancer later on. (Jiang, Chao, Culp, & Krishna, 2023)

    At the same time, AI is also changing the way we look for signs of pancreatic cancer in blood tests. It can find special markers in the blood that might mean someone has pancreatic cancer and understand complicated genetic information to figure out who might be more likely to get the disease (Tripathi et al., 2024). Another thing AI does well is look through lots of health records to find hidden patterns that show who might be at risk. This helps doctors decide who really needs to be checked for pancreatic cancer. (Tripathi et al., 2024)

    The important parts of using AI in checking for pancreatic cancer—like looking at images, finding markers in the blood, and studying health records—are all connected. They’re part of a big plan that uses AI to make sure we find pancreatic cancer early and accurately. This could help patients get better treatment sooner and have a better chance of surviving.

    The work that PRECEDE is doing, together with the use of AI, gives us a lot of hope for how we’ll be able to handle pancreatic cancer in the future. Creating a strong program to watch for this cancer isn’t just about science; it’s also a sign of hope for people who might get pancreatic cancer. It shows how working together across countries and never giving up on finding new solutions can make a big difference, even when things are tough.

    The ongoing research is bringing us closer to the goal of making pancreatic cancer something we can treat instead of something that can’t be cured. The hard work and commitment of the scientists, doctors, nurses, and patients involved in this research are what’s making this progress possible. If we keep supporting and funding research that helps us detect pancreatic cancer early, we might reach a time when this disease isn’t so scary anymore.

    In the end, the work being done by a global team to watch for pancreatic cancer is a huge leap in fighting this illness. The PRECEDE research and the use of AI show us what the future could look like, where we can find and stop pancreatic cancer early. We still have a long way to go in this fight, but these new tools make us more ready than ever to face it. The research that keeps going on is very important, and everyone is watching and hoping as we head into a new time of dealing with pancreatic cancer.

    REFERENCES

    1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019 Feb;10(1):10-27. doi: 10.14740/wjon1166. Epub 2019 Feb 26. PMID: 30834048; PMCID: PMC6396775.
    2. MUHC News. (2024, April 18). New findings illustrate pathway for screening high-risk individuals for pancreatic cancer. Montreal University Health Centre. https://muhc.ca/news-and-patient-stories/research/new-findings-illustrate-pathway-screening-high-risk-pancreatic
    3. Fortner, C. (2024, April 18). Montreal study examines screening approach to grow pancreatic cancer survival odds. CityNews Montreal. Retrieved from https://montreal.citynews.ca/2024/04/18/montreal-study-pancreatic-cancer-survival-odds/
    4. Zogopoulos, G., Haimi, I., Sanoba, S. A., Everett, J. N., Wang, Y., Katona, B. W., … & the PRECEDE Consortium. (2024). The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Journal of the National Comprehensive Cancer Network, 22(3). https://doi.org/10.6004/jnccn.2023.7097
    5. Pesheva, E. (2023, May 8). AI predicts future pancreatic cancer. Harvard Medical School. Retrieved from https://hms.harvard.edu/news/ai-predicts-future-pancreatic-cancer
    6. Huang B, Huang H, Zhang S, Zhang D, Shi Q, Liu J, Guo J. Artificial intelligence in pancreatic cancer. Theranostics. 2022 Oct 3;12(16):6931-6954. doi: 10.7150/thno.77949. PMID: 36276650; PMCID: PMC9576619.
    7. Katta, M.R., Kalluru, P.K.R., Bavishi, D.A., et al. (2023). Artificial intelligence in pancreatic cancer: Diagnosis, limitations, and the future prospects—a narrative review. Journal of Cancer Research and Clinical Oncology, 149(8), 6743–6751. https://doi.org/10.1007/s00432-023-04625-1
    8. Jiang J, Chao WL, Culp S, Krishna SG. Artificial Intelligence in the Diagnosis and Treatment of Pancreatic Cystic Lesions and Adenocarcinoma. Cancers (Basel). 2023 Apr 22;15(9):2410. doi: 10.3390/cancers15092410. PMID: 37173876; PMCID: PMC10177524.
    9. Tripathi, S., Tabari, A., Mansur, A., Dabbara, H., Bridge, C. P., & Daye, D. (2024). From machine learning to patient outcomes: A comprehensive review of AI in pancreatic cancer. Diagnostics, 14(2), 174. https://doi.org/10.3390/diagnostics14020174